Ghrelin Plasma Levels After 1 Year of Ketogenic Diet in Children With Refractory Epilepsy.
children
epilepsy
ghrelin
growth
ketogenic diet
Journal
Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
04
2019
accepted:
10
07
2019
entrez:
10
8
2019
pubmed:
10
8
2019
medline:
10
8
2019
Statut:
epublish
Résumé
The ketogenic diet (KD) is a high-fat, low carbohydrate nutritional treatment adopted in several countries for refractory epilepsy. However, the use of KD is limited by adverse events including growth retardation. In a previous investigation, we demonstrated that ghrelin is reduced in children maintained on KD for 3 months. As ghrelin regulates growth hormone (GH) secretion, it can be hypothesized that growth retardation depends on the reduced ghrelin availability. To assess this hypothesis, in this study we evaluate ghrelin and growth during 1 year of KD. We examined a small cohort of 6 children (2 males and 4 females, age range 3-10.4 years) affected by refractory epilepsy, who received the KD as add-on treatment. All patients were on drug polytherapy. Endpoints of the study were: (i) ghrelin plasma levels at 0, 15, 30, 90, and 365 days from KD onset, (ii) growth, and (iii) seizure control by ketogenesis. Ghrelin levels were -53 and -47% of basal levels, respectively, at 90 and 365 days (
Identifiants
pubmed: 31396519
doi: 10.3389/fnut.2019.00112
pmc: PMC6668051
doi:
Types de publication
Journal Article
Langues
eng
Pagination
112Références
J Am Diet Assoc. 1999 Dec;99(12):1573-5
pubmed: 10608955
Dev Med Child Neurol. 2002 Dec;44(12):796-802
pubmed: 12455855
J Am Diet Assoc. 2003 Jun;103(6):707-12
pubmed: 12778041
Regul Pept. 2004 Aug 15;120(1-3):261-7
pubmed: 15177945
Neurology. 2005 Dec 13;65(11):1808-9
pubmed: 16344528
Nat Neurosci. 2006 Mar;9(3):381-8
pubmed: 16491079
J Clin Invest. 2006 Mar;116(3):760-8
pubmed: 16511605
Biochem Biophys Res Commun. 2007 Aug 3;359(3):795-800
pubmed: 17560544
Lancet Neurol. 2008 Jun;7(6):500-6
pubmed: 18456557
Pediatrics. 2008 Aug;122(2):e334-40
pubmed: 18676520
Epilepsia. 2009 Feb;50(2):297-303
pubmed: 18727678
J Endocrinol. 2010 Jun;205(3):263-70
pubmed: 20351014
Peptides. 2011 Nov;32(11):2229-35
pubmed: 21781995
Epilepsia. 2012 Apr;53(4):585-95
pubmed: 22416903
Clin Nutr. 2013 Feb;32(1):98-103
pubmed: 22749312
Am J Physiol Regul Integr Comp Physiol. 2013 Jun 1;304(11):R980-90
pubmed: 23576609
PLoS One. 2013 Aug 28;8(8):e72716
pubmed: 24015271
J Child Neurol. 2014 Nov;29(11):1496-501
pubmed: 24309243
Front Neurol. 2014 Apr 29;5:63
pubmed: 24808888
Clin Endocrinol (Oxf). 2015 Jan;82(1):142-6
pubmed: 24810977
Epilepsy Behav. 2015 Aug;49:47-54
pubmed: 25934585
Mol Metab. 2015 Mar 21;4(6):437-60
pubmed: 26042199
Cell Metab. 2015 Sep 1;22(3):427-36
pubmed: 26278052
Endocrinology. 2016 Oct;157(10):3946-3957
pubmed: 27490185
Pharmaceuticals (Basel). 2017 Oct 20;10(4):null
pubmed: 29053577
Clin Nutr. 2019 Apr;38(2):954-957
pubmed: 29605572
Neurology. 2018 Jul 3;91(1):e62-e66
pubmed: 29802169
BMJ. 2018 Nov 14;363:k4583
pubmed: 30429127
Pediatr Surg Int. 2019 Jun;35(6):709-714
pubmed: 30838440